Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ: MNMD )

9.890 +1.240 (+14.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Via Benzinga
Exposures Product Safety
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. 
Via Talk Markets
Exposures Product Safety
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
From MindMed
Via Business Wire
What A Trip: Psychedelic Medicine Company MindMed Shares Rocket 50% After Positive Data
Shares of clinical stage biopharmaceutical company MindMed were heavily monitored on Friday after the stock rocketed higher during Thursday's cash session by more than 51% on more than 30x the... 
Via Talk Markets
Mind Medicine's Earnings Outlook
Via Benzinga
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
Via Benzinga
Exposures Product Safety
S&P 500 Gains 1%; Kroger Earnings Top Views
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 250 points on Thursday. The Dow traded up 0.34% to 38,793.79 while the NASDAQ rose 1.63% to 16,292.61. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. 
Via Benzinga
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Via Benzinga
Exposures Product Safety
What's Going On With MindMed Stock Thursday?
MindMed shares are trading higher Thursday after the company received FDA breakthrough therapy designation and announced positive study data 
Via Benzinga
Exposures Product Safety
Why Is MindMed (MNMD) Stock Up 32% Today?
MindMed stock is heading higher on Thursday as MNMD investors celebrate it getting breakthrough designation from the FDA! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning! 
Via InvestorPlace
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
From Mind Medicine (MindMed) Inc.
Via Business Wire
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%. 
Via Talk Markets
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
From MindMed
Via Business Wire
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
Via Benzinga
MindMed Reports 2023 Financial Results and Business Updates
From MindMed
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
From MindMed
Via Business Wire
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking... 
Via Talk Markets
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Why Is ARB IOT (ARBB) Stock Up 230% Today?
ARB IOT stock is taking off on Tuesday after providing investors with a shareholder update and heavy trading of ARBB shares this morning. 
Via InvestorPlace
Why Is MindMed (MNMD) Stock Up 8% Today?
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers. 
Via InvestorPlace
Exposures Product Safety
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
From MindMed
Via Business Wire
Elon Musk Says, 'If Drugs Helped My Productivity I'd Take Them' — This Psychedelic Bio-Tech Company Hopes To Help Build That Future
Via Benzinga
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address... 
Via Benzinga
Exposures Product Safety
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. 
Via Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.